細胞培養工学<br>Cell Culture Engineering (Advances in Biochemical Engineering/biotechnology)

個数：

細胞培養工学
Cell Culture Engineering (Advances in Biochemical Engineering/biotechnology)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    【重要ご説明事項】
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版／ページ数 168 p.
  • 言語 ENG
  • 商品コード 9783540340065
  • DDC分類 660

基本説明

Contents - S.S. Farid: Established Bioprocesses for Producing Antibodies as a Basis for Future Planning.- K.F. Wlaschin, W.-S. Hu: Fedbatch Culture and Dynamic Nutrient Feeding.- K. Konstantinov, et al.: The "Push- To-Low" Approach for Optimitzation of High- Density Perfusion Cultures of Animal Cells.- and more.

Full Description

Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.

Contents

Established Bioprocesses for Producing Antibodies as a Basis for Future Planning.- Fedbatch Culture and Dynamic Nutrient Feeding.- The "Push-to-Low" Approach for Optimization of High-Density Perfusion Cultures of Animal Cells.- Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture.- Engineering Cells for Cell Culture Bioprocessing - Physiological Fundamentals.